The U.S. Patent and Trademark Office (USPTO) issued two new patents requested by Pulmatrix – one for the expansion of…
Articles by Patrícia Silva, PhD
Chiesi recently completed a long-term study showing that its extra-fine, fixed-dose, triple combination inhaler Trimbow is more effective than Utibron (indacaterol and glycopyrronium)…
A combination of Verona Pharma’s COPD therapy candidate RPL554 and Spiriva (tiotropium) significantly improved patients’ lung function and appeared to ease…
Pulmatrix has licensed PUR0200, its investigative inhaled treatment for people with chronic obstructive pulmonary disease (COPD), to the Vectura Group to…
According to the Better Health Channel, a chest infection affects either the larger airways or the smaller air sacs…
Verona Pharma recently announced clinical development updates and interim results for the first half of 2017 for RPL554 as…
The European Union has approved Trimbow as a maintenance treatment for adults with moderate to severe chronic obstructive pulmonary disease.
Verona Pharma recently dosed the first patients in its Phase 2b clinical trial evaluating RPL554 as a maintenance treatment for…
We know dealing with COPD sometimes feels like an uphill battle, both for the patients and the caregivers. You feel like you’re not…
There is a broad spectrum of lung diseases, which is made up of any disease that causes the lungs to not function…